A Phase I Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics for a Single Dose of HRS-9821 Powder for Inhalation Administered in Healthy Subjects and Multiple Doses in Patients With COPD
NCT ID: NCT07116915
Last Updated: 2025-11-17
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
PHASE1
82 participants
INTERVENTIONAL
2025-08-11
2026-01-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Study on Single and Multiple Atomization Inhalation of HRS-9821 Suspension for Inhalation in Healthy Subjects and COPD Patients
NCT05622864
A Trial of HRS-9813 in Healthy Subjects
NCT06821464
A Study to Assess the Efficacy and Tolerance of HRS-2261 in Subjects With Refractory Chronic Cough
NCT05733533
Multicenter, Randomized, Double-blind, Placebo-controlled Phase II Trial to Evaluate the Efficacy and Safety of HRS-9813 in Subjects With Pulmonary Fibrosis
NCT07192939
Placebo-controlled, Single and Multiple Dose Study in Healthy Volunteers and Refractory Chronic Cough Patients to Assess the Safety, Tolerability, and Pharmacokinetics of Two Formulations of NTX-1175
NCT05628740
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
HRS-9821 Powder for Inhalation
Participants inhaled HRS-9821 powder either as a single dose or for 12 days.
HRS-9821 Powder for Inhalation.
HRS-9821 Powder for Inhalation.
HRS-9821 Powder for Inhalation placebo
Participants received a single dose or 12 consecutive days of inhaled powdered placebo with HRS-9821.
HRS-9821 Powder for Inhalation placebo
HRS-9821 Powder for Inhalation placebo
Moxifloxacin
Moxifloxacin is oral
Moxifloxacin Hydrochloride Tablets
Moxifloxacin Hydrochloride Tablets
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
HRS-9821 Powder for Inhalation.
HRS-9821 Powder for Inhalation.
HRS-9821 Powder for Inhalation placebo
HRS-9821 Powder for Inhalation placebo
Moxifloxacin Hydrochloride Tablets
Moxifloxacin Hydrochloride Tablets
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Body weight ≥45 kg, BMI 18-33 kg/m2 (both ends included)
3. The 12-lead ECG was normal or abnormal but clinically insignificant until randomization
4. Contraception was strict from the time informed consent was signed until 1 month (for subjects receiving HRS-9821/ placebo) or 3 months (for male subjects receiving moxifloxacin) after the last dose
5. All study regulations and procedures were followed and inhalation devices used in the study were used correctly during the study
6. Vital signs were normal at screening
7. Pulmonary function was normal during screening
8. No smoking or smoking cessation ≥12 months before screening, and previous smoking history \<5 pack-years；
10. Male or female, aged 40-75 years;
11. Patients diagnosed with COPD;
12. A post-bronchodilator FEV1 /FVC \< 0.7,40% ≤FEV1 \< 80% of the predicted value,;
13. Smoking history of≥ 10 pack-years;
14. Normal chest X-ray examination results at screening;
15. Supporting discontinuation of COPD-related medications before randomization；
Exclusion Criteria
2. Persons who had donated blood or had massive blood loss (\> 400 ml) within 4 weeks before screening or who were interested in donating blood during the study
3. Receipt of the investigational drug or device within 4 weeks before randomization or less than 5 times the half-life of the drug, whichever was greater;
4. Patients who had difficulty in blood collection or could not tolerate venipuncture in the past, such as dizzy with needles or blood
5. History of malignancy in any organ system
6. Known allergies to salbutamol, study medication, or any excipients in the formulation
7. Known previous infection with human immunodeficiency virus (HIV), hepatitis B virus (HBV) or hepatitis C virus (HCV); Or positive HIV (according to a trial-site SOP), treponema pallidum antibody, HBV surface antigen, or HCV antibody before randomization
8. History of alcohol abuse
9. History of drug abuse and drug dependence in the past 5 years；
10. Positive for alcohol or substance abuse test before randomization
11. During the study, surgery or treatment that might interfere with the conduct of the study was planned；
12. Unable or unwilling to fully adhere to the study protocol
13. Mentally or legally incapacitated
14. There were any other reasons for the subject not to participate in the study in the opinion of the investigator;
15. Use of a strong/moderate potency drug that inhibits or induces the hepatic drug-metabolizing enzyme CYP3A4 14 days before the first dose;
16. Drugs with effects on P-glycoprotein (P-gp) or breast cancer resistance protein (BCRP) were anticipated to be used during the study;
17. History of using HRS-9821 suspension;
18. Have been treated with antibiotics for upper and lower respiratory tract infections within 12 weeks prior to screening;
19. Abnormal laboratory or physical examination results with clinical significance;
20. Positive urine nicotine test before randomization;
22. History of life-threatening acute exacerbation of COPD (AECOPD), including admission to intensive care unit and/or need for invasive ventilator support;
23. Diagnosed with other respiratory disorders;
24. Pulmonary heart disease, or pulmonary hypertension caused by lung disease and/or hypoxia;
25. History of lung volume reduction surgery, partial lung resection, lung transplantation, and other surgeries that may affect pulmonary function results;
26. History of AECOPD requiring systemic glucocorticoids or antibiotics or hospitalization within 4 weeks prior to screening;
27. Lower respiratory tract infection requiring antibiotic treatment within 4 weeks prior to screening;
28. Requiring oxygen therapy or home non-invasive ventilation;
29. Currently using or plan to use non-selective beta blockers or other drugs with bronchoconstrictive effects during the study;
30. Patients with serious trauma or major surgery within 6 months prior to screening who are still in the recovery period;
31. Abnormal laboratory tests at screening and baseline.
18 Years
75 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Guangdong Hengrui Pharmaceutical Co., Ltd
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
West China Hospital, Sichuan University
Chengdu, Sichuan, China
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
HRS-9821-I-102
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.